A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
NCT ID: NCT00103454
Last Updated: 2016-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
288 participants
INTERVENTIONAL
2005-01-31
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
NCT00289198
Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action
NCT00118729
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)
NCT00197262
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
NCT00116883
Perennial Allergic Rhinitis Study In Pediatric Subjects
NCT00108914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
GW685698X
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW685698X
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must comply with study procedures and be literate.
Exclusion Criteria
* Use of corticosteroids.
* Use of allergy medications and some other medications during the study.
* Current tobacco use.
* Clinically significant abnormal ECG or laboratory abnormality.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Tallahassee, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Vero Beach, Florida, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Lilburn, Georgia, United States
GSK Investigational Site
South Bend, Indiana, United States
GSK Investigational Site
Metairie, Louisiana, United States
GSK Investigational Site
Portland, Maine, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
North Andover, Massachusetts, United States
GSK Investigational Site
North Dartmouth, Massachusetts, United States
GSK Investigational Site
Springfield, Massachusetts, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Lincoln, Nebraska, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Ocean City, New Jersey, United States
GSK Investigational Site
Summit, New Jersey, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Canton, Ohio, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Eugene, Oregon, United States
GSK Investigational Site
Lake Oswego, Oregon, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Providence, Rhode Island, United States
GSK Investigational Site
Orangeburg, South Carolina, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
New Braunfels, Texas, United States
GSK Investigational Site
Murray, Utah, United States
GSK Investigational Site
South Burlington, Vermont, United States
GSK Investigational Site
West Allis, Wisconsin, United States
GSK Investigational Site
Kelowna, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nathan R, Berger W, Yang W, Cheema A, Silvey MJ, Wu W, Faris M, Philpot E. Once daily fluticasone furoate* nasal spray (FFNS), a novel enhanced affinity steroid, provides 24-hour relief for the nasal symptoms of perennial allergic rhinitis (PAR) J Allergy
Nathan RA, Berger W, Yang W, Cheema A, Silvey M, Wu W, Philpot E. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008 May;100(5):497-505. doi: 10.1016/S1081-1206(10)60477-2.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FFR30002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.